sj-PNG-7-tmj-10.1177_03008916211014954 – Supplemental material for PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
posted on 2021-05-19, 12:09authored byRoberta Minari, Francesco Bonatti, Giulia Mazzaschi, Alessandra Dodi, Francesco Facchinetti, Francesco Gelsomino, Gloria Cinquegrani, Anna Squadrilli, Paola Bordi, Sebastiano Buti, Melissa Bersanelli, Alessandro Leonetti, Agnese Cosenza, Leonarda Ferri, Elena Rapacchi, Federico Quaini, Andrea Ardizzoni, Marcello Tiseo
Supplemental material, sj-PNG-7-tmj-10.1177_03008916211014954 for PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors by Roberta Minari, Francesco Bonatti, Giulia Mazzaschi, Alessandra Dodi, Francesco Facchinetti, Francesco Gelsomino, Gloria Cinquegrani, Anna Squadrilli, Paola Bordi, Sebastiano Buti, Melissa Bersanelli, Alessandro Leonetti, Agnese Cosenza, Leonarda Ferri, Elena Rapacchi, Federico Quaini, Andrea Ardizzoni and Marcello Tiseo in Tumori Journal